Inhaled beta2-agonists and death for asthma: can we overcome this risk?

M. Cazzola (Rome, Italy)

Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths
Disease area: Airway diseases

Slide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Rome, Italy). Inhaled beta2-agonists and death for asthma: can we overcome this risk?. Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled beta2-agonists in asthma management: an evolving story
Source: Breathe 2016; 12: 375-377
Year: 2016


Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD
Source: Eur Respir J 2010; 36: 494-502
Year: 2010



Is there a problem with inhaled corticosteroid use in COPD?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020


Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience
Source: ERJ Open Res, 8 (1) 00014-2022; 10.1183/23120541.00014-2022
Year: 2022



Inhaled therapies: can they breathe new life into asthma?
Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?
Year: 2019

Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?
Source: Eur Respir J, 53 (2) 1802112; 10.1183/13993003.02112-2018
Year: 2019



Inhaled corticosteroids in COPD: the case against
Source: Eur Respir J 2009; 34: 13-16
Year: 2009


Inhaled corticosteroids in COPD: a case in favour
Source: Eur Respir J 2009; 34: 10-12
Year: 2009


Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018


The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma
Source: Annual Congress 2009 - Epidemiology of atopy and asthma
Year: 2009

Does inhaled corticosteroid use affect the risk of ?COVID-19-related death?
Source: Breathe, 17 (1) 2000068; 10.1183/20734735.0275-2020
Year: 2021



Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020


The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015

Long-acting bronchodilators in COPD: where are we now and where are we going?
Source: Breathe 2014; 10:110-120
Year: 2014



Excess morbidity and mortality in patients with asthma on long-acting beta2-agonists
Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths
Year: 2007


Bronchodilator therapies for severe asthma
Source: Eur Respir Mon 2011; 51: 253-267
Year: 2011


Inhaled corticosteroids in the treatment of acute asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

Inhaled corticosteroids in preschool asthmatics: are they effective and who benefits most?
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014


Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking
Source: Eur Respir J 2006; 28: Suppl. 50, 454s
Year: 2006